{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:48:09Z","timestamp":1791136089633,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.mehy.2009.03.011","type":"journal-article","created":{"date-parts":[[2009,4,17]],"date-time":"2009-04-17T08:39:58Z","timestamp":1239957598000},"page":"153-155","source":"Crossref","is-referenced-by-count":13,"title":["Everolimus, a promising medical therapy for coronary heart disease?"],"prefix":"10.1016","volume":"73","author":[{"given":"Lei","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Tai","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2009.03.011_bib1","series-title":"The Atlas of heart disease and stroke","author":"Mackay","year":"2004"},{"key":"10.1016\/j.mehy.2009.03.011_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/3-540-27661-0_13","article-title":"Lipid and non-lipid effects of statins","author":"Paoletti","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.mehy.2009.03.011_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-2004-869592","article-title":"Lipid lowering therapy in atherosclerosis","volume":"4","author":"Aikawa","year":"2004","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.mehy.2009.03.011_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCULATIONAHA.108.191259","article-title":"Heart disease and stroke statistics \u2013 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2009.03.011_bib5","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1161\/CIRCULATIONAHA.105.540013","article-title":"Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events","volume":"114","author":"Waxman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2009.03.011_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.transproceed.2003.11.039","article-title":"Sirolimus: a ten-year perspective","volume":"36","author":"Kahan","year":"2004","journal-title":"Transplant P"},{"key":"10.1016\/j.mehy.2009.03.011_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2006.01.021","article-title":"TORgeting oncogene addiction for cancer therapy","volume":"9","author":"Choo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mehy.2009.03.011_bib8","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients","volume":"43","author":"Morrisett","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.mehy.2009.03.011_bib9","doi-asserted-by":"crossref","first-page":"H2721","DOI":"10.1152\/ajpheart.01174.2006","article-title":"Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells","volume":"292","author":"Ma","year":"2007","journal-title":"Am J Physiol \u2013 Heart C"},{"key":"10.1016\/j.mehy.2009.03.011_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jps.20751","article-title":"The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors","volume":"96","author":"Mathis","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.mehy.2009.03.011_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2169\/internalmedicine.47.0315","article-title":"Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina","volume":"47","author":"Sako","year":"2008","journal-title":"Internal Med"},{"key":"10.1016\/j.mehy.2009.03.011_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2006.11.023","article-title":"Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM","volume":"195","author":"Gou\u00ebffic","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mehy.2009.03.011_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.fjc.0000177985.14305.15","article-title":"Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis","volume":"46","author":"Pakala","year":"2005","journal-title":"J Cardiovasc Pharm"},{"key":"10.1016\/j.mehy.2009.03.011_bib14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jacc.2006.09.047","article-title":"Selective clearance of macrophages in atherosclerotic plaques by autophagy","volume":"49","author":"Verheye","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.mehy.2009.03.011_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ftd.0000179838.33020.34","article-title":"Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose","volume":"28","author":"Leung","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.mehy.2009.03.011_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007691-200010000-00006","article-title":"Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers","volume":"22","author":"Brattstr\u00f6m","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.mehy.2009.03.011_bib17","first-page":"987","article-title":"A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients","volume":"28","author":"Johnson","year":"1996","journal-title":"Transplant P"},{"key":"10.1016\/j.mehy.2009.03.011_bib18","doi-asserted-by":"crossref","first-page":"495S","DOI":"10.1016\/j.transproceed.2004.01.015","article-title":"The evolving experience using everolimus in clinical transplantation","volume":"36","author":"Formica","year":"2004","journal-title":"Transplant P"},{"key":"10.1016\/j.mehy.2009.03.011_bib19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.mehy.2009.03.011_bib20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/sj.bjc.6604636","article-title":"MTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?","volume":"99","author":"Le Tourneau","year":"2008","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.mehy.2009.03.011_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.mehy.2009.03.011_bib22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.mrrev.2008.06.001","article-title":"The mTOR pathway and its role in human genetic diseases","volume":"659","author":"Rosner","year":"2008","journal-title":"Mutat Res"},{"key":"10.1016\/j.mehy.2009.03.011_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","article-title":"Atherosclerosis. The road ahead","volume":"104","author":"Glass","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.mehy.2009.03.011_bib24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2009.03.011_bib25","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","article-title":"Pathogenesis of atherosclerosis","volume":"47","author":"Falk","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.mehy.2009.03.011_bib26","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2009.03.011_bib27","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1161\/01.ATV.0000174795.62387.d3","article-title":"Lipoprotein retention \u2013 and clues for atheroma regression","volume":"25","author":"Williams","year":"2005","journal-title":"Arterioscl Throm Vas"},{"key":"10.1016\/j.mehy.2009.03.011_bib28","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.mehy.2009.03.011_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","article-title":"Coronary plaque disruption","volume":"92","author":"Falk","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2009.03.011_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trre.2005.10.005","article-title":"Campistol. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions","volume":"20","author":"Julio Pascual","year":"2006","journal-title":"Transplant Rev"},{"key":"10.1016\/j.mehy.2009.03.011_bib31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11883-008-0034-y","article-title":"Autophagy in atherosclerosis","volume":"10","author":"Martinet","year":"2008","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.mehy.2009.03.011_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/cvr\/cvm103","article-title":"Rapamycin modulates the eNOS vs shear stress relationship","volume":"78","author":"Cheng","year":"2008","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.mehy.2009.03.011_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2007.09.019","article-title":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-\/- mice despite severe hypercholesterolemia","volume":"198","author":"Mueller","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mehy.2009.03.011_bib34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/eurheartj\/ehi571","article-title":"Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation","volume":"27","author":"Hofma","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mehy.2009.03.011_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacc.2005.01.062","article-title":"Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction","volume":"46","author":"Togni","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.mehy.2009.03.011_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/ATVBAHA.108.166736","article-title":"Discovery of the role of wall shear in atherosclerosis","volume":"29","author":"Caro","year":"2009","journal-title":"Arterioscl Throm Vas"},{"key":"10.1016\/j.mehy.2009.03.011_bib37","doi-asserted-by":"crossref","first-page":"I214","DOI":"10.1161\/CIRCULATIONAHA.105.000471","article-title":"Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine","volume":"114","author":"Ramzy","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2009.03.011_bib38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.surg.2004.05.007","article-title":"Aortic eNOS expression and phosphorylation in Apo-E knockout mice. differing effects of rapamycin and simvastatin","volume":"136","author":"Naoum","year":"2004","journal-title":"Surgery"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987709001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987709001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T14:39:31Z","timestamp":1589726371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987709001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0306987709001959"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2009.03.011","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}